Skip to main content

Table 1 Association between KCF-S “RING C1x-C1x-C1y(C1z)-C1y(C2x)-C1y-C1x-C1x-C1z(C5a+O7a)-C1z(C1a)” and KEGG pathway hsa04080 Neuroactive “ligand-receptor interaction”. See also Fig. 4

From: Network-based characterization of drug-protein interaction signatures with a space-efficient approach

KCF-S

RING C1x-C1x-C1y(C1z)-C1y(C2x)-C1y-C1x-

 

C1x-C1z(C5a+O7a)-C1z(C1a)

Pathway

hsa04080 Neuroactive ligand-receptor interaction

Drug

D00952 Megestrol acetate (antineoplastic)

 

D01299 Chlormadinone acetate (progestin)

 

D01368 Cyproterone acetate (anti-androgen)

Protein

hsa:10800 cysteinyl leukotriene receptor 1

 

hsa:1128-hsa:1133 muscarinic acetylcholine receptor M1 - M5

 

hsa:1134 nicotinic acetylcholine receptor alpha-1

 

hsa:1268 cannabinoid receptor 1

 

hsa:134,hsa:135,hsa:140 adenosine A1 receptor A1, A2a, A3

 

hsa:146,hsa:150,hsa:151 adrenergic receptor alpha-1D,2A,2B

 

hsa:1511 cathepsin G

 

hsa:152 adrenergic receptor alpha-2C

 

hsa:153-hsa:155 adrenergic receptor beta-1,2,3

 

hsa:1812-hsa:1816 dopamine receptor D1-D5

 

hsa:185-hsa:186 angiotensin II receptor type 1,2

 

hsa:1909-hsa:1910 endothelin receptor type A, B

 

hsa:2908 glucocorticoid receptor

 

hsa:3269,hsa:3274 histamine receptor H1,H2

 

hsa:3356,hsa:3357,hsa:3358 5-hydroxytryptamine receptor 2

 

hsa:3362 5-hydroxytryptamine receptor 6

 

hsa:4159-hsa:4161 melanocortin receptor 3,4,5

 

hsa:4886,hsa:4887 neuropeptide Y receptor type 1/4/6,2

 

hsa:4985 delta-type opioid receptor

 

hsa:4986 kappa-type opioid receptor

 

hsa:4988 mu-type opioid receptor

 

hsa:552 arginine vasopressin receptor 1A

 

hsa:5724 platelet-activating factor receptor

 

hsa:624 bradykinin receptor B2

 

hsa:6865,hsa:6869 tachykinin receptor 1,2

 

hsa:7068 thyroid hormone receptor beta

 

hsa:7253 thyroid stimulating hormone receptor

 

hsa:7433 vasoactive intestinal peptide receptor 1

 

hsa:886 cholecystokinin A receptor